Alterations in 2 or more of the PTEN, RB1, and TP53 tumor suppressor genes may identify patients with prostate cancer of an aggressive variant (AVPC),24 who may benefit from intensified platinum-containing chemotherapy for metastatic castration-resistant prostate cancer.25 This evidence concerns the gene PTEN and prostate cancer.